Primary biliary cholangitis: a comprehensive overview

Ana Lleo, Simona Marzorati, Juan Manuel Anaya, M. Eric Gershwin

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by biliary destruction, progressive cholestasis, and potentially liver cirrhosis. Patients develop a well-orchestrated immune reaction, both innate and adaptive, against mitochondrial antigens that specifically targets intrahepatic biliary cells. A puzzling feature of PBC is that the immune attack is predominantly organ specific, although the mitochondrial autoantigens are found in all nucleated cells. The disease results from a combination of genetic and environmental risk factors; however, the exact pathogenesis remains unclear. Serologically, PBC is characterized by presence of antimitochondrial antibodies, which are present in 90–95 % of patients and are often detectable years before clinical signs appear. Like other complex disorders, PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. A significant number of patients develop end-stage liver disease and eventually require liver transplantation. Recent studies from large international cohorts have better identified prognostic factors, suggesting a change in patient management based on risk stratification. Therapeutic options are changing. In this review we discuss data on the autoimmune responses and treatment of the disease.

Original languageEnglish (US)
Pages (from-to)485-499
Number of pages15
JournalHepatology International
Volume11
Issue number6
DOIs
StatePublished - Nov 1 2017

Fingerprint

Cholangitis
End Stage Liver Disease
Cholestasis
Autoantigens
Autoimmunity
Liver Cirrhosis
Liver Transplantation
Autoimmune Diseases
Disease Progression
Liver Diseases
Therapeutics
Antigens
Antibodies

Keywords

  • Antimitochondrial antibodies
  • Biliary epithelial cells
  • Epigenetics
  • Genetics
  • Obeticholic acid
  • Primary biliary cholangitis
  • Prognostic factors
  • UDCA

ASJC Scopus subject areas

  • Hepatology

Cite this

Primary biliary cholangitis : a comprehensive overview. / Lleo, Ana; Marzorati, Simona; Anaya, Juan Manuel; Gershwin, M. Eric.

In: Hepatology International, Vol. 11, No. 6, 01.11.2017, p. 485-499.

Research output: Contribution to journalReview article

Lleo, Ana ; Marzorati, Simona ; Anaya, Juan Manuel ; Gershwin, M. Eric. / Primary biliary cholangitis : a comprehensive overview. In: Hepatology International. 2017 ; Vol. 11, No. 6. pp. 485-499.
@article{8a028bf8cbca4737b1142c98bd75dde9,
title = "Primary biliary cholangitis: a comprehensive overview",
abstract = "Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by biliary destruction, progressive cholestasis, and potentially liver cirrhosis. Patients develop a well-orchestrated immune reaction, both innate and adaptive, against mitochondrial antigens that specifically targets intrahepatic biliary cells. A puzzling feature of PBC is that the immune attack is predominantly organ specific, although the mitochondrial autoantigens are found in all nucleated cells. The disease results from a combination of genetic and environmental risk factors; however, the exact pathogenesis remains unclear. Serologically, PBC is characterized by presence of antimitochondrial antibodies, which are present in 90–95 {\%} of patients and are often detectable years before clinical signs appear. Like other complex disorders, PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. A significant number of patients develop end-stage liver disease and eventually require liver transplantation. Recent studies from large international cohorts have better identified prognostic factors, suggesting a change in patient management based on risk stratification. Therapeutic options are changing. In this review we discuss data on the autoimmune responses and treatment of the disease.",
keywords = "Antimitochondrial antibodies, Biliary epithelial cells, Epigenetics, Genetics, Obeticholic acid, Primary biliary cholangitis, Prognostic factors, UDCA",
author = "Ana Lleo and Simona Marzorati and Anaya, {Juan Manuel} and Gershwin, {M. Eric}",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s12072-017-9830-1",
language = "English (US)",
volume = "11",
pages = "485--499",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Primary biliary cholangitis

T2 - a comprehensive overview

AU - Lleo, Ana

AU - Marzorati, Simona

AU - Anaya, Juan Manuel

AU - Gershwin, M. Eric

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by biliary destruction, progressive cholestasis, and potentially liver cirrhosis. Patients develop a well-orchestrated immune reaction, both innate and adaptive, against mitochondrial antigens that specifically targets intrahepatic biliary cells. A puzzling feature of PBC is that the immune attack is predominantly organ specific, although the mitochondrial autoantigens are found in all nucleated cells. The disease results from a combination of genetic and environmental risk factors; however, the exact pathogenesis remains unclear. Serologically, PBC is characterized by presence of antimitochondrial antibodies, which are present in 90–95 % of patients and are often detectable years before clinical signs appear. Like other complex disorders, PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. A significant number of patients develop end-stage liver disease and eventually require liver transplantation. Recent studies from large international cohorts have better identified prognostic factors, suggesting a change in patient management based on risk stratification. Therapeutic options are changing. In this review we discuss data on the autoimmune responses and treatment of the disease.

AB - Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by biliary destruction, progressive cholestasis, and potentially liver cirrhosis. Patients develop a well-orchestrated immune reaction, both innate and adaptive, against mitochondrial antigens that specifically targets intrahepatic biliary cells. A puzzling feature of PBC is that the immune attack is predominantly organ specific, although the mitochondrial autoantigens are found in all nucleated cells. The disease results from a combination of genetic and environmental risk factors; however, the exact pathogenesis remains unclear. Serologically, PBC is characterized by presence of antimitochondrial antibodies, which are present in 90–95 % of patients and are often detectable years before clinical signs appear. Like other complex disorders, PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. A significant number of patients develop end-stage liver disease and eventually require liver transplantation. Recent studies from large international cohorts have better identified prognostic factors, suggesting a change in patient management based on risk stratification. Therapeutic options are changing. In this review we discuss data on the autoimmune responses and treatment of the disease.

KW - Antimitochondrial antibodies

KW - Biliary epithelial cells

KW - Epigenetics

KW - Genetics

KW - Obeticholic acid

KW - Primary biliary cholangitis

KW - Prognostic factors

KW - UDCA

UR - http://www.scopus.com/inward/record.url?scp=85034650779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034650779&partnerID=8YFLogxK

U2 - 10.1007/s12072-017-9830-1

DO - 10.1007/s12072-017-9830-1

M3 - Review article

C2 - 29164395

AN - SCOPUS:85034650779

VL - 11

SP - 485

EP - 499

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 6

ER -